Tag: Oticon Medical



Oticon Neuro System Receives FDA Premarket Approval

Oticon Medical announced that the US Food and Drug Administration (FDA) has granted premarket approval (PMA) to the company’s Neuro System to treat individuals 18 years or older, with bilateral severe-to-profound sensorineural hearing loss, who obtain limited benefit from appropriately fitted hearing aid(s).

Two New Bone-anchored Implant Products Gain FDA Clearance

The FDA has cleared two new Oticon Medical products for marketing in the US: The Minimally Invasive Ponto Surgery (MIPS), an update of the tissue preservation surgery for use with the company’s Ponto System; and the Ponto BHX Implant, which has a laser-ablated titanium surface that promotes a faster and stronger bonding to bone, and is designed to increase the strength of the bone-to-implant interface by more than 150%.

Read More

Oticon Medical Appoints Jared Schnackenberg as President US

Oticon Medical announced the appointment of Jared Schnackenberg as president of Oticon Medical US. He will provide overall leadership for the entire US organization to further develop Oticon Medical’s position in the bone anchored hearing solutions (BAHS) market and to prepare for the anticipated launch of Oticon Medical Cochlear Implants for the US market.

Read More